医药周报 20260130 从 JPM 大会挖掘 FIC 靶点三期数据验证节点 glmszqdatemark 医药行情回顾&分析&近期判断 周专题：从 JP Morgan 大会看 2026 MNC 密集验证新靶点 风险提示：1）医保、集采政策导致价格不及预期；2）临床进度或上市时间不及预期；3）行业竞争 格局的不确定性；4）地缘政治风险；5）下游投融资及需求复苏不及预期。 2026 年 02 月 01 日 推荐 维持评级 [Table_Author] | 分析师 张金洋 | | --- | | 执业证书： S0590525120012 | | 邮箱： zhangjinyang@glms.com.cn | | 分析师 胡偌碧 | | 执业证书： S0590525120011 | | 邮箱： huruobi@glms.com.cn | | 分析师 王彦迪 | | 执业证书： S0590525120015 | | 邮箱： wangyandi@glms.com.cn | 相对走势 -10% 7% 23% 40% 2025/2 2025/8 2026/1 医药 沪深300 相关研究 本公司具备证券投资咨询业务资格，请务 ...

Investment Rating - The industry maintains a "Neutral" rating, with specific company ratings of "Buy" for 恒瑞医药 (Hengrui Medicine) and "Increase" for 药明康德 (WuXi AppTec) [12][60]. Core Insights - The report highlights significant collaborations in the innovative drug sector, including 石药集团 (Shijiazhuang Yiling Pharmaceutical) partnering with AstraZeneca for long-acting peptide drug development and receiving clinical trial approval for SYS6055 injection in China [8][37]. - The report emphasizes the robust R&D capabilities of Chinese pharmaceutical companies showcased at the 2026 JPM Healthcare Conference, suggesting investment opportunities in innovative drugs, CXO, and upstream life sciences [12][60]. - The report notes the recent release of the revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China," which aims to enhance drug innovation and regulatory processes [19][20]. Industry Data - As of January 29, 2026, the SW Pharmaceutical and Biological Industry's price-to-earnings ratio (TTM) is 51.60 times, with a valuation premium of 259% relative to the CSI 300 index [10][52]. - The report provides current prices for vitamin raw materials, with Vitamin B1 at 237.5 RMB/kg and Vitamin D3 at 130 RMB/kg, remaining stable compared to January 28 [22]. - The Chinese herbal medicine market index shows a decline of 15% year-on-year, with specific herbs like 党参 (Codonopsis) and 当归 (Angelica) experiencing price drops of 41% and 29% respectively [26]. Company Announcements - 先声药业 (Xiansheng Pharmaceutical) signed an exclusive licensing agreement with Boehringer Ingelheim for the dual-specific antibody SIM0709, with potential milestone payments reaching up to 1.016 billion euros [36]. - 恒瑞医药 (Hengrui Medicine) received acceptance for a drug listing application and clinical trial approval for multiple products, including a breakthrough therapy designation for HRS-5346 [39][40]. - 诺诚健华 (Innovent Biologics) anticipates a revenue of approximately 2.365 billion RMB for 2025, marking a 134% year-on-year increase [41].

很多人至今还在问：坐拥几千亿，身边围着全世界最聪明的脑袋和最尖端的药，怎么就换不回一条命？ 这恰恰是赵宁留给世人最硬核的最后一课，在生物学的铁壁面前，钞票有时候真的只是一堆纸。 2023年温州女首富抗癌失败，即使名下有两家医药上市公司，市值高达3700亿元，最后还是拯救不了自 己。 站在2026年1月的凛冽寒风里，回望三年前的那个初夏，你会发现那是一个极其充满张力的时刻。 2023年5月，两块屏幕上的画面构成了最残酷的蒙太奇。一块屏幕上，药明康德与药明生物的市值红线 狂舞，那个数字最终定格在惊人的3700亿元。这庞大的商业帝国掌控着全球95%顶尖药企的研发命脉。 而在另一块心电监护仪的屏幕上，57岁的赵宁，这条红线被拉成了无限延长的直线。这位帝国的缔造者 之一、温州女首富，在与癌症死磕了整整20年后，还是没能跑赢死神。 这不仅仅是一则富豪讣告，这是一个关于"药神"救不了自己，却无意间救了时代的悲剧。 但这堆"纸"并非毫无意义，要读懂它的重量，我们得把时钟拨回到千禧年。 那时候的赵宁和李革，刚从哥伦比亚大学拿到博士学位，在美国的大药企里混得风生水起。2000年，两 口子受邀回北大演讲，这一趟回国，直接把他们的" ...

Core Insights - InSilico Medicine leverages its generative AI platform, Pharma.AI, to enhance drug discovery efficiency, having developed multiple promising pipelines and established collaborations with several multinational pharmaceutical companies, creating a significant competitive advantage [1][14]. Industry Background - AI-driven drug discovery and development (AIDD) is becoming an increasingly important trend in the pharmaceutical industry, with AI technology applicable in both early and late stages of drug development, improving efficiency in target identification, molecular design, and clinical trial optimization [2][5]. - The global AIDD market is projected to grow from $11.9 billion in 2023 to $74.6 billion by 2032, with a compound annual growth rate (CAGR) of 22.6% [2]. Business Model - InSilico Medicine operates a dual CEO structure, integrating generative AI with drug discovery and development through a collaborative operational model, focusing on prioritizing targets, molecular design, and optimizing experimental protocols [14]. - The company’s revenue model includes drug discovery and pipeline development, software solutions, and other discovery-related businesses, primarily generating income through licensing and collaboration agreements [14]. Pipeline Development - The company has developed a robust pipeline with over 20 assets in clinical or IND application stages, covering areas such as fibrosis, oncology, immunology, metabolism, and pain management [18][20]. - InSilico Medicine has established partnerships with 13 of the top 20 global pharmaceutical companies, reflecting strong confidence in its platform and pipeline [21][22]. Financial Performance - InSilico Medicine's revenue has shown rapid growth, reaching $30.15 million in 2022, $51.18 million in 2023, and $85.83 million in 2024, although the company remains in a loss position [25][26]. - The company’s R&D expenses were $35.57 million in the first half of 2025, a 22% decrease year-on-year, indicating a focus on cost management [25]. Conclusion - The application of AI in drug discovery allows companies to explore previously overlooked targets at lower costs, increasing opportunities for first-in-class drugs [28]. - Despite challenges in the industry, AI in drug development holds significant potential, with InSilico Medicine positioned as a key player in the Chinese AI pharmaceutical market, continuously enhancing its pipeline and expanding its licensing efforts [32].

Core Viewpoint - The CDMO (Contract Development and Manufacturing Organization) business of multinational companies in China is not just shrinking but appears to be disappearing, with only a few remaining players like Boehringer Ingelheim still operating in the market [2][10]. Group 1: Current State of CDMO in China - The CDMO business in China has seen a significant decline, with major players like Lonza and Thermo Fisher Scientific facing operational challenges and even selling their facilities [5][6][8]. - Boehringer Ingelheim remains one of the few foreign CDMO companies still active in China, primarily due to securing a contract for the production of BeiGene's PD-1 drug [10]. - The CDMO market in China is experiencing a transformation, with many foreign companies exiting or downsizing their operations due to insufficient orders and market conditions [7][10]. Group 2: Market Dynamics and Trends - The implementation of the 2019 Drug Administration Law in China marked a turning point for the CDMO market, allowing for a separation of production and marketing licenses, thus lowering barriers for research-focused pharmaceutical companies [12]. - Despite the advantages of a large workforce and lower costs in China, many foreign CDMO companies have struggled to establish a foothold due to high pricing models that do not align with local market conditions [13][14]. - The Chinese CDMO market has grown significantly, with a compound annual growth rate of 39.9% from 2018 to 2023, increasing from 16 billion RMB to 85.9 billion RMB, and is expected to reach 208.4 billion RMB by 2028 [16]. Group 3: Future Outlook - Domestic CDMO companies are increasingly matching or surpassing the capabilities of foreign counterparts, offering higher efficiency and lower prices, which positions them favorably in the market [16][17]. - The evolution of the Chinese CDMO industry has transitioned from reliance on foreign technology and policy support to a focus on technological development and global capacity expansion [16].

Core Insights - The CDMO (Contract Development and Manufacturing Organization) business of multinational companies in China is experiencing significant decline, with many exiting the market entirely [1][8] - The Chinese CDMO market is growing rapidly, with a compound annual growth rate of 39.9% from 2018 to 2023, and is expected to reach 208.4 billion RMB by 2028 [16] Group 1: Multinational CDMO Operations in China - Multinational companies like Lonza, Thermo Fisher, and Merck have faced challenges in their CDMO operations in China, with many either closing facilities or selling them off [4][5][6] - Lonza's Guangzhou factory, which was operational for only three years, was sold to a local company due to insufficient orders [4] - Thermo Fisher's factory in Hangzhou is struggling with low order volumes, and its future remains uncertain [5][6] Group 2: Local CDMO Developments - Zhaoyan Biotech's new manufacturing base in Guangzhou, which focuses on large molecule CDMO, signifies a strategic move to enhance capacity and create a collaborative platform for biopharmaceutical innovation in Southeast Asia [3] - Local companies are increasingly building their own production capabilities, reducing reliance on foreign CDMO services [14] Group 3: Market Dynamics and Trends - The introduction of the MAH (Marketing Authorization Holder) system in 2019 has lowered production barriers, allowing more companies to utilize CDMO services [11] - Despite the advantages of a large workforce and lower costs, foreign CDMOs have struggled to establish a foothold in China due to high pricing models that do not align with local market conditions [12][13] - The efficiency and cost-effectiveness of Chinese CDMOs are becoming competitive with their foreign counterparts, leading to a shift in market dynamics [15][16]

恒生医疗低开低走大跳水，截至收盘下跌2.54%。石药集团大跌10.2%，药明康德下跌3.81%，中国生物 下跌3.35%，三生制药、药明生物等多股跌幅在2%上方。 恒生银行低开低走终结四连涨，截至收盘下跌1.63%。建设银行大跌3.06%，民生银行、重庆农村商业 银行、农业银行、交通银行、工商银行等近10只个股跌幅在2%上方。 低开低走后全天震荡下行，截至收盘恒生指数大跌2.08%。恒生医疗跌幅居前，大消费、互联网、银行 等紧随其后。 大消费低开低走大跳水，截至收盘下跌2.21%。周大福下跌6.74%，吉利汽车下跌4.23%，比亚迪股份、 农夫山泉、泡泡玛特、安踏体验、百威亚大等超10只个股跌幅在3%上方。 内容只是个人观点，仅供参考，不作为投资依据！欢迎关注交流，互相学习、共同探讨！ ...

Group 1 - The pharmaceutical sector experienced a pullback, with the pharmaceutical ETF (159929) declining by 1.53% and a trading volume exceeding 1.3 billion yuan, indicating a net inflow of over 45 million yuan during the day, marking 11 consecutive days of capital inflow totaling over 360 million yuan [1][3] - Major stocks within the pharmaceutical ETF saw most decline, including Meien Health and Pianzaihuang dropping over 3%, WuXi AppTec and Aier Eye Hospital falling over 2%, while Tigermed rose over 7% [3][4] - Tigermed is projected to see a net profit growth of 105% to 204% by 2025, indicating strong future performance [3] Group 2 - The JPM 2026 conference highlighted a shift in the global pharmaceutical industry's focus towards the effective allocation and long-term value realization of innovations amidst rising uncertainties [5] - Chinese innovation is gaining global recognition, with increased participation from Chinese companies at the JPM 2026, reflecting a growing acknowledgment from international capital and multinational pharmaceutical companies [5][6] - The evaluation logic of multinational pharmaceutical companies regarding Chinese innovative assets is evolving, focusing on their efficacy, differentiation, and competitive positioning for inclusion in global product portfolios [6][10] Group 3 - Multinational pharmaceutical companies are entering a critical patent cliff period, necessitating diversification in their pipelines to mitigate risks associated with single products and treatment areas [10][12] - The integration of AI into core strategies is becoming mainstream, with AI being utilized to enhance R&D efficiency and optimize operational systems, thus addressing challenges posed by the patent cliff [12][13] - The oncology sector remains a core area for pharmaceutical innovation, with a focus on antibody-drug conjugates (ADCs) and cell therapies, indicating a robust pipeline and commercial potential [13][15]

Summary of Key Points from Conference Call Records Industry Overview 1. Baijiu Industry - The baijiu industry is experiencing cautious expectations for sales during the Spring Festival, with a decrease in the willingness of distributors to collect payments. However, Moutai shows strong demand resilience, with its price rebounding. The misalignment of the Spring Festival holiday is expected to benefit Q1 2026, and policies to stimulate domestic demand may be implemented, leading to increased dividend yields for leading companies and maintaining strong profitability [1][3][5]. 2. Paper Industry - The profitability in the paper industry is shifting towards upstream sectors due to high pulp prices and weak downstream consumption, resulting in narrowed profits for midstream operations. It is anticipated that wood chip and pulp prices will continue to rise in Q1, driving up paper prices. Companies with their own pulp production capacity are expected to see sustained profitability [1][7][8]. 3. Forestry Carbon Sink - China is actively promoting forestry carbon sinks as part of its national climate strategy. Companies capable of developing forestry carbon sinks and possessing forestry resources are worth attention, as the cost-effectiveness of forestry carbon sinks is the highest [1][9]. 4. New Consumption Sector - Leading companies in the new consumption sector, such as Laopu Gold, are currently undervalued with strong performance expectations. The rise in gold prices and discount promotions are driving sales growth. Laopu Gold significantly raised prices in the second half of last year, and substantial growth is expected this year [1][10][11]. 5. Home Appliance Industry - The home appliance industry is showing signs of bottoming out, with expectations for a reversal post-Spring Festival. The implementation of trade-in subsidies is expected to improve retail performance. TCL Electronics is integrating Sony's TV business, opening up profitability potential, and is currently undervalued [1][17][19]. Company-Specific Insights 1. Moutai and Other Baijiu Brands - Moutai is recommended as a key investment due to its undeniable competitiveness. Other notable brands include Luzhou Laojiao, Gujing Gongjiu, and Shanxi Fenjiu, which have significant advantages in competitiveness and operational capabilities, with opportunities to increase market share [1][6]. 2. Paper Companies - Recommended paper companies include Nine Dragons Paper, Sun Paper, and Yueyang Forest Paper, which are expected to see continuous profit improvements due to their upstream integration [1][7][8]. 3. New Consumption Leaders - Key investment opportunities in the new consumption sector include Laopu Gold, which is expected to achieve a performance of 7 to 8 billion yuan in 2026, corresponding to a P/E ratio of about 16 times, reflecting a 50% growth compared to 2025 [1][11][12]. 4. Gold and Jewelry Sector - The gold and jewelry sector is entering a bull market, with companies like Taibai Gang showing significant profit growth and low P/E ratios, indicating substantial potential. The sector is expected to benefit from promotional activities during Valentine's Day and the Spring Festival [1][13]. 5. Livestock and Meat Industry - The livestock sector, particularly beef and pork, is facing supply pressures, with pig prices in a downward cycle. However, the beef market is expected to see price support due to tight supply conditions [1][20][21][23][22]. 6. Pharmaceutical Manufacturing - The CRO, raw materials, and intermediates sectors in pharmaceutical manufacturing are poised for growth in 2026, driven by changes in supply and demand dynamics. Companies like WuXi AppTec and Junshi Biosciences are highlighted as key players in this space [1][24][25]. Additional Insights - The overall sentiment in the market indicates a cautious but optimistic outlook for various sectors, with specific companies showing strong potential for growth and profitability amidst changing market conditions [1][2][4][10][18].

Core Viewpoint - The medical sector is showing signs of recovery in 2026, driven by policy clarity and the realization of innovative outcomes, leading to increased investment interest in medical ETFs [1][19]. Group 1: Current Core Logic and Positive Factors in the Medical Sector - The transition from "selling expectations" to "performance realization" is evident, with domestic medical device innovations gaining global recognition, thus becoming a new growth engine for the industry [3][21]. - The medical sector is experiencing a high proportion of companies meeting or exceeding their 2025 performance forecasts, indicating a favorable industry outlook [3][21]. - The recent surge in AI medical technologies is not just speculative but demonstrates clear cost-reduction and efficiency-enhancing capabilities in hospital operations and drug development [4][23]. Group 2: Policy Environment Changes - The policy environment has shifted from a "speed over quality" approach to one of "value co-creation," with recent signals indicating a more favorable stance on centralized procurement and medical insurance negotiations [6][24]. - Optimizations in the approval process for innovative medical devices and continuous improvements in procurement rules are expected to enhance the competitive landscape and restore profitability for companies [8][26]. - The introduction of a market exclusivity period in the revised Drug Administration Law is expected to boost long-term investment confidence in pharmaceutical R&D [9][27]. Group 3: Financial Support for Medical Equipment Updates - The national "two new" policy, focusing on large-scale equipment updates and consumer goods replacement, has allocated 62.5 billion yuan in special bonds to support medical equipment upgrades, benefiting listed companies in the medical device sector [10][28]. - There is a significant demand for replacing outdated medical equipment in domestic healthcare institutions, coupled with policies favoring domestic alternatives, leading to increased orders and market share for leading companies in imaging, surgical robots, and in-vitro diagnostics [10][28]. Group 4: Reasons for Recent Fund Inflows into Medical ETF (512170) - The medical ETF (512170) has seen substantial inflows, with a single-day capital increase of 499 million yuan on January 28, 2026, and a total of 1.8 billion yuan over nine consecutive trading days, reflecting a shift in market sentiment towards value recovery [1][19][14]. - The medical ETF is currently one of the largest medical-themed ETFs in A-shares, with a market size exceeding 26 billion yuan, driven by high cost-effectiveness and a consensus on bottom valuations [14][32]. - The ETF closely tracks the CSI Medical Index, with significant allocations in medical devices (53.17%) and medical services, making it an attractive option for both institutional and retail investors [14][32][34].